Robert W. Baird restated their outperform rating on shares of Henry Schein Inc. (NASDAQ:HSIC) in a report released on Tuesday morning. Robert W. Baird currently has a $176.00 price target on the stock, up from their previous price target of $175.00.
HSIC has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Henry Schein from a hold rating to a sell rating in a research note on Tuesday, September 20th. Bank of America Corp. began coverage on shares of Henry Schein in a research note on Monday, September 12th. They issued a buy rating and a $185.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Henry Schein currently has an average rating of Hold and an average target price of $157.92.
Shares of Henry Schein (NASDAQ:HSIC) opened at 161.77 on Tuesday. The stock’s 50 day moving average is $162.61 and its 200 day moving average is $170.46. The firm has a market cap of $13.23 billion, a price-to-earnings ratio of 27.40 and a beta of 1.05. Henry Schein has a 12-month low of $140.11 and a 12-month high of $183.00.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.01. Henry Schein had a net margin of 4.42% and a return on equity of 17.84%. The business had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the prior year, the business earned $1.46 EPS. Henry Schein’s quarterly revenue was up 9.3% on a year-over-year basis. Equities analysts expect that Henry Schein will post $6.57 earnings per share for the current year.
In other news, Director Paul Brons sold 3,381 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The shares were sold at an average price of $164.03, for a total transaction of $554,585.43. Following the completion of the sale, the director now owns 13,715 shares of the company’s stock, valued at approximately $2,249,671.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.27% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Riverhead Capital Management LLC increased its position in shares of Henry Schein by 998.9% in the second quarter. Riverhead Capital Management LLC now owns 453,851 shares of the company’s stock valued at $80,241,000 after buying an additional 412,549 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Henry Schein by 55.7% in the second quarter. UBS Asset Management Americas Inc. now owns 802,401 shares of the company’s stock valued at $141,865,000 after buying an additional 286,976 shares during the last quarter. Janus Capital Management LLC increased its position in shares of Henry Schein by 16.5% in the second quarter. Janus Capital Management LLC now owns 2,027,848 shares of the company’s stock valued at $358,522,000 after buying an additional 286,929 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Henry Schein by 11.7% in the first quarter. BlackRock Fund Advisors now owns 2,313,748 shares of the company’s stock valued at $399,422,000 after buying an additional 243,031 shares during the last quarter. Finally, Virginia Retirement Systems ET AL bought a new position in shares of Henry Schein during the second quarter valued at approximately $32,832,000. 91.98% of the stock is owned by institutional investors and hedge funds.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.